Rituximab, marketed under brand names like Rituxan and MabThera, is a chimeric monoclonal antibody used to treat certain autoimmune diseases and cancers [1]. The patent landscape for rituximab is complex, involving multiple patents covering its composition, manufacturing, and methods of use [2].
When does rituximab exclusivity expire?
The original patents for rituximab have expired, allowing for the development and approval of biosimilars [3]. For instance, the U.S. Food and Drug Administration (FDA) approved the first biosimilar to Rituxan in 2015 [4]. However, additional patents and exclusivities related to specific formulations, indications, or manufacturing processes may have had later expiration dates [2]. DrugPatentWatch.com provides detailed information on patent expiry timelines for various drugs, including rituximab [2].
What are biosimilars of rituximab?
Biosimilars are biological products that are highly similar to an already approved reference biologic product, with no clinically meaningful differences in safety, purity, and potency [5]. Several biosimilars of rituximab have been developed and approved in various markets. These include products like biosimilar rituximab-abbs (Truxima) and biosimilar rituximab-pvvr (Herzuma) in the United States [4, 6].
How do rituximab biosimilars work?
Biosimilars function in the same way as their reference product because they are structurally and functionally highly similar [5]. Rituximab targets the CD20 protein found on the surface of B cells. By binding to CD20, it triggers the immune system to attack and destroy these B cells, which is beneficial in treating conditions where B cells play a harmful role [1]. Biosimilars of rituximab replicate this mechanism of action.
What is the difference between rituximab and its biosimilars?
The primary difference between rituximab and its biosimilars lies in their development and manufacturing. Biosimilars are developed to be highly similar, but not identical, to the reference product due to inherent variability in biological manufacturing processes [5]. Regulatory agencies evaluate biosimilarity based on extensive analytical, non-clinical, and clinical data to ensure no significant differences exist in safety or efficacy compared to the reference product [5].
Why are companies challenging rituximab patents?
Companies developing biosimilar versions of rituximab often challenge existing patents. This is a common strategy in the pharmaceutical industry to clear a path for market entry once their biosimilar is developed and ready for regulatory approval [3]. Patent challenges can target patents covering manufacturing processes, specific formulations, or methods of use that might otherwise extend the market exclusivity of the originator product [2].
What are the approved uses for rituximab?
Rituximab is approved for the treatment of several conditions. These include certain types of non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, and microscopic polyangiitis [1]. Biosimilars are typically approved for all the indications for which the reference product is approved.
Sources:
[1] https://www.gene.com/media/products/rituxan
[2] https://drugpatentwatch.com/
[3] https://www.fda.gov/drugs/biosimilars/understanding-biosimilars
[4] https://www.fda.gov/drugs/biosimilars/biosimilar-and-interchangeable-biosimilar-approvals
[5] https://www.fda.gov/drugs/biosimilars
[6] https://www.fda.gov/drugs/resources-information-approved-drugs/herzuma-rituximab-pvvr